Comments |
The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene The tumor grows progressively in the A/Jax subline of the Strong A mouse and kills 100% of the animals. In contrast, mice of the resistant C57BL/6K strain reject the tumor in about 100% of the cases. The SaI variant (ATCC CRL-2543) grows as an ascites tumor when inoculated intraperitoneally, while the SaI/N variant grows as a solid tumor when inoculated subcutaneously The cell line can be used as a model for testing immunotherapy protocols. It can be used in immunology and cancer studies. The cells may be used for transfection studies. |
References |
Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917
Baker P, et al. Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and the C57BL/6K mouse. Ann. N.Y. Acad. Sci. 101: 46-63, 1962.
Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J. Natl. Cancer Inst. 13: 1299-1377, 1953. PubMed: 13035452
Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.
Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.
Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.
Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.
|